Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.8.0.1
Note 11 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Net sales $ 163,973 $ 144,037 $ 462,739 $ 406,425
Operating income 43,084 33,502 93,263 80,538
Costs recognized on sale of acquired inventory     (2,013) (2,770)
Amortization of acquisition related intangible assets     (34,611)  
Corporate general, selling, and administrative expenses (53,285) (49,409) (175,349) (151,814)
Acquisition Related [Member]        
Corporate general, selling, and administrative expenses (1,015) (707) (5,652) (2,999)
Operating Segments [Member]        
Operating income 63,462 54,502 173,056 150,611
Intersegment Eliminations [Member]        
Net sales (143) (43) (306) (80)
Segment Reconciling Items [Member]        
Costs recognized on sale of acquired inventory (1,431) (637) (2,013) (2,770)
Amortization of acquisition related intangible assets (11,872) (11,689) (34,547) (33,504)
Acquisition related expenses (1,312) (3,993) (23,994) (19,581)
Stock based compensation (4,748) (3,974) (13,587) (11,219)
Biotechnology [Member] | Operating Segments [Member]        
Net sales 110,029 94,516 306,516 267,256
Operating income 53,013 45,242 143,826 127,195
Protein Platforms [Member] | Operating Segments [Member]        
Net sales 25,539 23,586 79,566 64,707
Operating income 2,461 3,256 11,636 5,308
Diagnostics [Member] | Operating Segments [Member]        
Net sales 28,548 25,978 76,963 74,542
Operating income $ 7,988 $ 6,004 $ 17,594 $ 18,108